Evaluation of current practice: Management of chemotherapy-related toxicities

Anti-Cancer Drugs

Volumn 22, Issue 9, 2011, Pages 919-925

  Lheureux, Stéphanie ^a   Clarisse, Bénédicte ^a   Launay Vacher, Vincent ^b   Gunzer, Katharina ^a   Delcambre Lair, Corinne ^a   Bouhier Leporrier, Karine ^a,d   Kaluzinski, Laure ^e   Maron, Dominique ^f   Ngo, Minh Dung ^g   Grossi, Sara ^a   Dubois, Brice ^b   Zalcman, Gérard ^c   Joly, Florence ^a,c  

^a CENTRE FRANÇOIS BACLESSE   (France)

^b Centre de Traitement des Données du Cancéropôle Nord Ouest   (France)

^c CHU CÔTE DE NACRE   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e Louis Pasteur Hospital   (France)

^f Polyclinique Avranches ^*  (France)

^g Jacques Monod Hospital   (France)

Author keywords

chemotherapy; haematological toxicities; practice assessment; predictive factors; toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; SERUM ALBUMIN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL PRACTICE; CREATININE CLEARANCE; DIGESTIVE TOXICITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSESTHESIA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOALBUMINEMIA; INFECTION; KIDNEY FUNCTION; LUNG TOXICITY; LYMPHOCYTE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RISK FACTOR; SKIN TOXICITY; SOLID TUMOR; THROMBOCYTOPENIA; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 80052505923     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328349d7f1     Document Type: Article

References (37)

1. Homan ER. Quantitative relationships between toxic doses of antitumorchemotherapeutic agents in animals and man. Cancer Chemother Rep 3 1972; 3:13-19
2. Grochow LB, Baraldi C, Noe D. Is dose normalization to weight or bodysurface area useful in adults? J Natl Cancer Inst 1990; 82:323-325 (Pubitemid 20097710)
3. Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001 J Natl Cancer Inst 2002; 94:1883-1888 (Pubitemid 36104633)
4. Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 2007; 25:4707-4713 (Pubitemid 350086471)
5. Petain A, Chatelut E. Anticancer drug dose individualisation: from body surface area to physiology. Bull Cancer 2008; 95:895-901
6. Launay-Vacher V, Svetlana K, Deray G. Anticancéreux. 2005; 3e éd. Paris: Méditions International; 2005
7. Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007; 43:14-34 (Pubitemid 46070218)
8. Li YF, Fu S, Hu W, Liu JH, Finkel KW, Gershenson DM, et al. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer 2007; 17:739-763 (Pubitemid 47063315)
9. Balducci L, Stanta G. Cancer in the frail patient: a coming epidemic. Hematol Oncol Clin North Am 2000; 14:235-250. (Pubitemid 30078440)
10. Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology (Williston Park) 2000; 14 (11A):221-227
11. Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007; 43:14-34 (Pubitemid 46070218)
12. Launay-Vacher V, Deray G. Pharmacokinetic modifications with renal insuffiency. Oncologie 2004; 6:283-286
13. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110:1376-1384 (Pubitemid 47435612)
14. Murry DJ, Riva L, Poplack DG. Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int J Cancer Suppl 1998; 11:48-51
15. Alvarez-Cabellos R, Garcia-Carbonero R, Garcia-Lacalle C, Gomez P, Tercero A, Sanchez D, et al. Fluorouracil-based chemotherapy in patients with gastrointestinal malignancies: influence of nutritional folate status on toxicity. J Chemother 2007; 19:744-749 (Pubitemid 351212026)
16. Kaikani W, Bachmann P. Consequences of a comorbidity often neglected in oncology: malnutrition. Bull Cancer 2009; 96:659-664
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41
18. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl 1):S1-S266
19. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE).Version 30, DCTD, NCI, NIH, DHHS. August 9, 2006 Available at: http://ctep.cancer.gov/forms/CTCAEv3pdf. [Accessed 16 July 2007]. 2010.
20. Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 2002; 38:1677-1684
21. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low doseintensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003; 21:4524-4531 (Pubitemid 46594022)
22. Roila F, Lupattelli M, Sassi M, Basurto C, Bracarda S, Picciafuoco M, et al. Intra and interobserver variability in cancer patients' performance status assessed according to karnofsky and ECOG scales. Ann Oncol 1991; 2:437-439
23. Roila F, Lupattelli M, Sassi M, Basurto C, Bracarda S, Picciafuoco M, et al. Intra and interobserver variability in cancer patients' performance status assessed according to karnofsky and ECOG scales. Ann Oncol 1991; 2:437-439
24. Hurria A, Hurria A, Brogan K, Panageas KS, Pearce C, Norton L, et al. Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer. Drugs Aging 2005; 22:785-791
25. De Jong FA, Van der Bol JM, Mathijssen RH, Van Gelder T, Wiemer EA, Sparreboom A, et al. Renal function as a predictor of irinotecan-induced neutropenia. Clin Pharmacol Ther 2008; 84:254-262
26. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the Renal Insufficiency and Anticancer Medications (IRMA) study. Cancer 2007; 110:1376-1384 (Pubitemid 47435612)
27. Ray-Coquard I, Le Cesne A, Rubio MT, Mermet J, Maugard C, Ravaud A, et al. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group J Clin Oncol 1999; 17:2840-2846 (Pubitemid 29415242)
28. Blay JY, Le Cesne A, Mermet C, Maugard C, Ravaud A, Chevreau C, et al. A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood 1998; 92:405-410. (Pubitemid 28323701)
29. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al.The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038-3051 (Pubitemid 30644129)
30. Alexandre J, Gross-Goupil M, Falissard B, Nguyen ML, Gornet JM, Misset JL, et al. Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. Ann Oncol 2003; 14:36-41 (Pubitemid 36150256)
31. Arrieta O, Michel Ortega RM, Villanueva-Rodriguez G, Serna-Thome MG, Flores-Estrada D, Diaz-Romero C, et al. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer 2010; 10:50.
32. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038-3051 (Pubitemid 30644129)
33. Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology 2000; 14 (11A):221-227
34. Alexandre J, Gross-Goupil M, Falissard B, Nguyen ML, Gornet JM, Misset JL, et al. Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. Ann Oncol 2003; 14:36-41 (Pubitemid 36150256)
35. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187-3205 (Pubitemid 46638957)
36. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006; 42:2433-2453 (Pubitemid 44442936)
37. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003; 21:4524-4531 (Pubitemid 46594022)